Synthesis of flurbiprofen thiadiazole urea derivatives and assessment of biological activities and molecular docking studies

ZENGİN KURT B., Altundağ Ö., Tokgöz M. N., ÖZTÜRK CİVELEK D., Tuncay F., Cakmak U., ...Daha Fazla

CHEMICAL BIOLOGY & DRUG DESIGN, cilt.102, sa.6, ss.1458-1468, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 102 Sayı: 6
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1111/cbdd.14336
  • Dergi Adı: CHEMICAL BIOLOGY & DRUG DESIGN
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database, Index Chemicus (IC)
  • Sayfa Sayıları: ss.1458-1468
  • Anahtar Kelimeler: cytotoxcity, flurbiprofen, molecular docking, thiadiazole ring, tyrosinase inhibition, urea
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Totally 15 novel flurbiprofen urea derivatives were synthesized bearing the thiadiazole ring. Their inhibition effects on tyrosinase were determined. 3c was found to be the strongest inhibitor with the IC50 value of 68.0 mu M against tyrosinase. The enzyme inhibition types of the synthesized compounds were determined by examining the kinetic parameters. The inhibition type of 3c was determined as uncompetitive and the K-i value was calculated as 36.3 mu M. Moreover, their cytotoxic effects on hepatocellular carcinoma (HepG2), colorectal carcinoma (HT-29), and melanoma (B16F10) cell lines were evaluated. According to the cytotoxicity results, 3l (IC50 = 14.11 mu M) showed the highest cytotoxicity on the HT-29 cells, while 3o (IC50 = 4.22 mu M) exhibited the strongest cytotoxic effect on HepG2 cell lines. Also, 3j (IC50 = 7.55 mu M strongly affected B16F10. The effects of synthesized compounds on the healthy cell line were evaluated on the CCD-986Sk cell line. Molecular modelling studies have indicated the potential binding interactions of the uncompetitive inhibitor 3c with the enzyme-substrate complex.